By |


UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Contact Information

Website: www.ucb.com
Email: Antje.Witte@ucb.com
Main Phone: +32 25599999
Address: 60, Allee de la Recherche
City / Town: Brussels
Country: BEL
Postal Code: 1070

Issuer Information

Exchange: OTO
Employees: 7563
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 42.75 $ 0. (0.00%)
Last Price 42.75 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close 42.75
Last Trade Volume 8 52 Wk Hi 46.69 52 Wk Low 36.40
Market Cap 16.1 bi Ex-Div Date Div Rate 0.44 Yield 1.0350
Shares 376,243,778.00 EPS (TTM) 2.80 PE Ratio 16.40 Exchange OTCPK